Scarica l'app Stockscreener
4.36
1.16%
0.05
Dopo l'orario di chiusura:
4.50
0.14
+3.21%
Precedente Chiudi:
$4.31
Aprire:
$4.31
Volume 24 ore:
486.42K
Relative Volume:
1.02
Capitalizzazione di mercato:
$257.63M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
83.21
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
+3.32%
1M Prestazione:
-8.02%
6M Prestazione:
-7.23%
1 anno Prestazione:
-14.68%
Intervallo 1D:
$4.31
$4.45
Intervallo di 1 settimana:
$4.14
$4.45
Portata 52W:
$3.8092
$5.545
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Confronta VNDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.36 | 254.67M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Pharmaceuticals Receives Strong Buy Rating Amidst Growth in Key Product Lines and Promising FDA Decision on Bysanti - AInvest
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
Vanda (VNDA) Q2 Revenue Rises 4% - AOL.com
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - Jammu Links News
What is the dividend policy of Vanda Pharmaceuticals Inc. stockSuperior returns - Jammu Links News
What makes Vanda Pharmaceuticals Inc. stock price move sharplyCapitalize on high-yield stocks early - Jammu Links News
Is Vanda Pharmaceuticals Inc. stock overvalued or undervaluedCapitalize on emerging growth stocks - Jammu Links News
What are Vanda Pharmaceuticals Inc. company’s key revenue driversRapidly growing investment returns - Jammu Links News
What institutional investors are buying Vanda Pharmaceuticals Inc. stockRapid growth trajectories - Jammu Links News
What catalysts could drive Vanda Pharmaceuticals Inc. stock higher in 2025Unlock your portfolio’s full growth potential - Jammu Links News
Why is Vanda Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize portfolio value with timely trades - Jammu Links News
What are the technical indicators suggesting about Vanda Pharmaceuticals Inc.Maximize your portfolio’s earning power - Jammu Links News
Is Vanda Pharmaceuticals Inc. a growth stock or a value stockDiscover stocks with massive upside potential - Jammu Links News
Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Phenomenal wealth increase - Jammu Links News
How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Get professional advice for market timing - Jammu Links News
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Vanda Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 502% - AInvest
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising Expenses - GuruFocus
Vanda: Q2 Earnings Snapshot - Norwalk Hour
Vanda Pharmaceuticals' Q2 2025: Navigating Contradictions in Bysanti, PONVORY, and DTC Strategies - AInvest
Vanda Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Vanda Pharmaceuticals Q2 2025 misses EPS and revenue forecasts - Investing.com Nigeria
Vanda Pharmaceuticals: Navigating Q2 Earnings Disappointment Amid High-Stakes Pipeline Progress - AInvest
Vanda Pharmaceuticals Sees Strong Fanapt Growth Despite Rising Losses - Finimize
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Q2 2025 Earnings: EPS Misses at -$0.46, Revenue Falls Short at $52.6 Million - GuruFocus
Vanda Pharmaceuticals' Q2 2025 Earnings: A Turning Point in Pipeline Execution and Commercialization - AInvest
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results - ADVFN Brasil
How volatile is Vanda Pharmaceuticals Inc. stock compared to the marketMarket Forecast Data Feed Backed By Experts - jammulinksnews.com
Exploring US High Growth Tech Stocks For Potential Portfolio Expansion - simplywall.st
How Vanda Pharmaceuticals Inc. stock performs during market volatilityExit Ready Momentum Stock Watchlist Expanded - metal.it
Price Channel Expanding on Vanda Pharmaceuticals Inc.’s ChartROI Boosting Trade Opportunity Calendar Published - metal.it
Vanda Pharmaceuticals Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Bronstein, Gewirtz & Grossman, LLC Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH) - ACCESS Newswire
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionFast Entry High Potential Stock Alerts Triggered - metal.it
Vanda Pharmaceuticals VNDA 2025Q2 Earnings Preview Upside Potential on Strong Revenue Forecast - AInvest
How does Vanda Pharmaceuticals Inc. generate profit in a changing economyBuild a diversified portfolio for stability - jammulinksnews.com
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):